WO2023194911 - CELLS EXPRESSING AN ANTI-MESOTHELIN CAR
National phase entry:
Publication Number
WO/2023/194911
Publication Date
12.10.2023
International Application No.
PCT/IB2023/053431
International Filing Date
04.04.2023
Title **
[English]
CELLS EXPRESSING AN ANTI-MESOTHELIN CAR
[French]
CELLULES EXPRIMANT UN CAR ANTI-MÉSOTHÉLINE
Applicants **
GAMMADELTA THERAPEUTICS LTD
Inventors
KOVACS, Istvan
SIMOES, Andre Goncalo do Espirito Santo
ILLINGWORTH, Sam
NUSSBAUMER, Oliver
EDWARDS, Sarah
Priority Data
2204927.4
04.04.2022
GB
63/482,752
01.02.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5495 | |
| EPO | Filing, Examination, Granting | 99388 | |
| Japan | Filing, Examination, Granting | 4841 | |
| South Korea | Filing, Examination, Granting | 7666 | |
| USA | Filing, Examination, Granting | 26390 |
Total:
143,780
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Some aspects of the present disclosure are directed to engineered innate lymphoid cells comprising a heterologous targeting construct specific for mesothelin and uses thereof. Some aspects of the present disclosure are directed to polynucleotides encoding a chimeric antigen receptor (CAR) that specifically binds human mesothelin, host cells comprising the polynucleotide, and methods of treating a disease or condition in a subject using the same.[French]
Certains aspects de la présente invention concernent des cellules lymphoïdes innées modifiées comprenant une construction de ciblage hétérologue spécifique pour la mésothéline et leurs utilisations. Certains aspects de la présente invention concernent des polynucléotides codant pour un récepteur antigénique chimérique (CAR) qui se lie spécifiquement à la mésothéline humaine, des cellules hôtes comprenant le polynucléotide, et des procédés de traitement d'une maladie ou d'un état chez un sujet l'utilisant.